Lipid-lowering agents also known ascholesterol-lowering, hypolipidemic, or antihyperlipidemic agents are a group of drugs used to reduce high levels oflipids(fats) and lipoproteins (fats with protein) in the blood. These drugs are used to treatcardiovascularabnormalities such asatherosclerosis(build-up...
Any of a class of lipid-lowering drugs that reduce serum cholesterol levels by inhibiting a key enzyme involved in the biosynthesis of cholesterol. [From the names of such lipid-lowering drugs aspravastatin.] American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 20...
Beliefs and attitudes may be specific to particular drugs. Messages can be aligned to dispel any generally held concerns or misconceptions and can help to inform conversations on issues that may be of particular importance to the patient, such as diet, adverse events, and cost. Strengths and ...
The present invention is a method introducing the sublingual placement of statin drugs whose names include: Fluvastatin, Atorvastatin, Lovastatin, Pravastatin and Simvastatin for heart related and other vascular emergencies. Current research challenges are developing many new derivatives and new classes of ...
Drug safety communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. Updated January 19, 2016. Accessed February 1, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-...
Few significant side effects were observed in clinical trials, and post-marketing reports of adverse events have been very limited when considered in comparison to the very large number of persons safely receiving these drugs. Even so, these drugs are not entirely free of side effects, and as ...
Moreover, the combination of a proton pump inhibitor with 2 CYP3A4-metabolized drugs also did not demonstrate an increased risk of CV events. These data represent one of the largest study populations to address the question of a possible drug鈥揹rug interaction between these classes of drugs. ...
No support in the form of grants, gifts, equipment, and/or drugs was provided. Author information Authors and Affiliations Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan Nobuyuki Hor...
Financial statement No support in the form of grants, gifts, equipment, and/or drugs was provided. Author details 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. 2Department of ...
Taken together, these data demonstrate that KLFs are critical modulators of the effects of statins on endothelial cells, and that increased expression of KLFs may represent a mechanism by which these drugs inhibit the activation of endothelial cells and monocytes by APLA/anti-β2GPI antibodies. ...